Drug Profile

Aspirin/rosuvastatin/telmisartan

Alternative Names: CP-103; rosuvastatin-telmisartan-ASA

Latest Information Update: 06 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CardioPharma
Class Acetates; Analgesics; Antihyperlipidaemics; Antihypertensives; Antineoplastics; Antipyretics; Antirheumatics; Benzimidazoles; Benzoates; Benzoic acids; Fluorobenzenes; Heart failure therapies; Nonsteroidal anti-inflammatories; Pyrimidines; Salicylic acids; Small molecules; Sulfonamides
Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

06 Jan 2026 Investigation in Cardiovascular disorders in USA (unspecified route) prior to January 2026 (CardioPharma pipeline, January 2026).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com